John J Barron, Vincent J Willey, Brett T Doherty, Ozgur Tunceli, Craig R Waltz, Michael Grabner, Daniel C Beachler, Stephan Lanes, Mark J Cziraky
{"title":"医疗保健综合研究数据库（HIRD）作为药物流行病学研究的真实世界数据源。","authors":"John J Barron, Vincent J Willey, Brett T Doherty, Ozgur Tunceli, Craig R Waltz, Michael Grabner, Daniel C Beachler, Stephan Lanes, Mark J Cziraky","doi":"10.1002/pds.70110","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and methods: </strong>The Healthcare Integrated Research Database (HIRD) is a large, comprehensive real-world data (RWD) source for health-related research. Demographic and healthcare-related characteristics of individuals are sourced from routinely updated RWD. The HIRD includes health insurance claims and other health-related information for individuals enrolled in health insurance plans offered or managed by Elevance Health and has been utilized for research for almost two decades. Individuals in the HIRD reside throughout the United States. Data in the HIRD have been available since January 2006, and are updated monthly.</p><p><strong>Results: </strong>As of July 2024, the researchable population of the HIRD included over 91 million individuals with medical benefits, and over 24 million individuals were actively enrolled. The median age of individuals in the HIRD is 36 years (interquartile range [IQR]: 22, 54), and 50% of individuals in the HIRD are female. The median duration of continuous enrollment in the HIRD is 2.0 years (IQR: 0.8, 4.7). For those actively enrolled, the median duration of continuous enrollment is 3.8 years (IQR: 1.7, 8.3). Other important characteristics of the HIRD include the ability to trace data back to their source, support both deterministic and probabilistic linkage with external data sources, and link family members within health plans.</p><p><strong>Conclusions: </strong>The HIRD has been a trusted resource to generate real-world evidence for a variety of health-related research, including regulatory-required safety studies, comparative effectiveness studies, and health economics and outcomes research.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 2","pages":"e70110"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798679/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Healthcare Integrated Research Database (HIRD) as a Real-World Data Source for Pharmacoepidemiologic Research.\",\"authors\":\"John J Barron, Vincent J Willey, Brett T Doherty, Ozgur Tunceli, Craig R Waltz, Michael Grabner, Daniel C Beachler, Stephan Lanes, Mark J Cziraky\",\"doi\":\"10.1002/pds.70110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and methods: </strong>The Healthcare Integrated Research Database (HIRD) is a large, comprehensive real-world data (RWD) source for health-related research. Demographic and healthcare-related characteristics of individuals are sourced from routinely updated RWD. The HIRD includes health insurance claims and other health-related information for individuals enrolled in health insurance plans offered or managed by Elevance Health and has been utilized for research for almost two decades. Individuals in the HIRD reside throughout the United States. Data in the HIRD have been available since January 2006, and are updated monthly.</p><p><strong>Results: </strong>As of July 2024, the researchable population of the HIRD included over 91 million individuals with medical benefits, and over 24 million individuals were actively enrolled. The median age of individuals in the HIRD is 36 years (interquartile range [IQR]: 22, 54), and 50% of individuals in the HIRD are female. The median duration of continuous enrollment in the HIRD is 2.0 years (IQR: 0.8, 4.7). For those actively enrolled, the median duration of continuous enrollment is 3.8 years (IQR: 1.7, 8.3). Other important characteristics of the HIRD include the ability to trace data back to their source, support both deterministic and probabilistic linkage with external data sources, and link family members within health plans.</p><p><strong>Conclusions: </strong>The HIRD has been a trusted resource to generate real-world evidence for a variety of health-related research, including regulatory-required safety studies, comparative effectiveness studies, and health economics and outcomes research.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"34 2\",\"pages\":\"e70110\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798679/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.70110\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70110","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
The Healthcare Integrated Research Database (HIRD) as a Real-World Data Source for Pharmacoepidemiologic Research.
Background and methods: The Healthcare Integrated Research Database (HIRD) is a large, comprehensive real-world data (RWD) source for health-related research. Demographic and healthcare-related characteristics of individuals are sourced from routinely updated RWD. The HIRD includes health insurance claims and other health-related information for individuals enrolled in health insurance plans offered or managed by Elevance Health and has been utilized for research for almost two decades. Individuals in the HIRD reside throughout the United States. Data in the HIRD have been available since January 2006, and are updated monthly.
Results: As of July 2024, the researchable population of the HIRD included over 91 million individuals with medical benefits, and over 24 million individuals were actively enrolled. The median age of individuals in the HIRD is 36 years (interquartile range [IQR]: 22, 54), and 50% of individuals in the HIRD are female. The median duration of continuous enrollment in the HIRD is 2.0 years (IQR: 0.8, 4.7). For those actively enrolled, the median duration of continuous enrollment is 3.8 years (IQR: 1.7, 8.3). Other important characteristics of the HIRD include the ability to trace data back to their source, support both deterministic and probabilistic linkage with external data sources, and link family members within health plans.
Conclusions: The HIRD has been a trusted resource to generate real-world evidence for a variety of health-related research, including regulatory-required safety studies, comparative effectiveness studies, and health economics and outcomes research.
期刊介绍：
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
